Dynamics of Chronic Myeloid Leukemia Under Imatinib Treatment: A Study of Resistance Development

被引：0

作者：

Badralexi, Irina ^{[1
]}

Bordei, Ana-Maria ^{[2
]}

Halanay, Andrei ^{[3
]}

Radulescu, Ileana Rodica ^{[1
]}

机构：

[1] Natl Univ Sci & Technol, Politehn Bucharest, Dept Math Methods & Models, Bucharest 060042, Romania

[2] Natl Inst Aerosp Res Elie Carafoli INCAS Bucharest, Bucharest 061126, Romania

[3] Natl Univ Sci & Technol, Politehn Bucharest, Dept Math & Informat, Bucharest 060042, Romania

来源：

MATHEMATICS | 2024年 / 12卷 / 24期

关键词：

chronic myeloid leukemia; asymmetric division; immune system; imatinib; delay differential equations; MATHEMATICAL-MODEL; DELAY SYSTEMS; STABILITY; HEMATOPOIESIS; BIOLOGY; CELLS;

D O I：

10.3390/math12243937

中图分类号：

O1 [数学];

学科分类号：

0701 ; 070101 ;

摘要：

Chronic myeloid leukemia (CML) is a hematological disorder characterized by the abnormal proliferation of leukemic cells. This study aims to model the dynamics of leukemic and healthy cell populations in CML, considering the role of the immune system and the effects of treatment with Imatinib. The model also addresses the development of treatment resistance in cells, following the Goldie-Coldman hypothesis. We employ a system of delay differential equations to simulate the interactions between leukemic cells, healthy cells, and the immune system under treatment. The results provide insights into the dynamic balance between leukemic cells, healthy cells, and immune responses, and the impact of developing resistance on treatment outcomes.

引用

页数：17

共 50 条

[31] An anthropometric study in children with chronic myeloid leukemia on imatinib
Goteke, Vamshi Krishna Reddy
Maddi, Rahul Narayan
Thota, Narender Kumar
Coca, Pragnya
Nagalla, Balakrishna
Linga, Vijay Gandhi
Gundeti, Sadashivudu
Digumarti, Raghunadharao
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[32] RXRA MEDIATED REVERSAL OF IMATINIB RESISTANCE IN CHRONIC MYELOID LEUKEMIA A TRANSCRIPTOMIC PROFILING STUDY
Vidhyadharan, Rakhi
Illangeswaran, Raveen
Rajamani, Bharathi
Benjamin, Esther
Das, Saswati
Mathews, Vikram
Velayudhan, Shaji
Balasubramanian, Poonkuzhali
EXPERIMENTAL HEMATOLOGY, 2024, 137
[33] Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate
Garipidou, V
Vakalopoulou, S
Tziomalos, K
ONCOLOGIST, 2005, 10 (06): : 457 - 458
[34] Comparison of Dasatinib, Nilotinib, and Imatinib in the Treatment of Chronic Myeloid Leukemia
Ciarcia, Roberto
Damiano, Sara
Puzio, Maria Valeria
Montagnaro, Serena
Pagnini, Francesco
Pacilio, Carmen
Caparrotti, Giuseppe
Bellan, Cristiana
Garofano, Tiziana
Polito, Maria Sole
Giordano, Antonio
Florio, Salvatore
JOURNAL OF CELLULAR PHYSIOLOGY, 2016, 231 (03) : 680 - 687
[35] MicroRNA improves the efficacy of imatinib on the treatment of chronic myeloid leukemia
Yi, Bin
Ma, Ruixia
Feng, Xiangling
Xing, Zhiwei
Zhang, Xiaoguo
Piazza, Gary
Xi, Yaguang
CANCER RESEARCH, 2014, 74 (19)
[36] Tuberculous Lymphadenitis Complicating Imatinib Treatment For Chronic Myeloid Leukemia
Yaghmour, B.
Romero-Legro, I.
Muthiah, M.
Freire, A.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
[37] Comparison of the Efficacy of Nilotinib and Imatinib in the Treatment of Chronic Myeloid Leukemia
Zhang, Bang-Shuo
Chen, Yong-Ping
Lv, Jing-Long
Yang, Yi
JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2019, 29 (07): : 631 - 634
[38] Generic imatinib in the treatment of chronic myeloid leukemia: Cerrahpasa experience
Eskazan, Ahmet Emre
Soysal, Teoman
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2016, 22 (02) : 382 - 384
[39] Criteria and treatment of insufficient responses to imatinib in chronic myeloid leukemia
Rousselot, Philippe
HEMATOLOGIE, 2006, 12 : 19 - 25
[40] Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells
Baran, Yusuf
Ural, Ali Ugur
Gunduz, Ufuk
HEMATOLOGY, 2007, 12 (06) : 497 - 503

← 1 2 3 4 5 →